GTBP News and Press, GT Biopharma Inc. From 03/04/21

GT Biopharma (GTBP) announces the addition of the University of Wisconsin's Madison Carbone Cancer Center as a new clinical trial site for its ongoing GTB-3550 TriKE multicenter Phase I/II trial, testing the treatment in certain patients with acute myeloid leukemia ((AML)).GTB-...

GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment PR Newswire BEVERLY HILLS, Calif. , March 4, 2021 /PRNewswire/ --&#...

GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials PR Newswire BEVERLY HILLS, Calif. , Feb. 18, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a c...

GT Biopharma (GTBP) announces the closing of an underwritten public offering of 4.3M units, with gross proceeds of about $23.6M.Each unit consisted of one GT Biopharma share and one warrant to purchase one share at a public offering price of $5.50/share, per unit.The transaction successfully ...

Successful completion of NASDAQ uplist Financing extinguished over $25M in debt and consolidated capital structure to 20,637,000 shares issued and outstanding Cash runway extended through 2022 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceuti...

GT Biopharma Appoints Two New Independent Directors PR Newswire BEVERLY HILLS, Calif. , Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell ...

GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550 PR Newswire BEVERLY HILLS, Calif. , Jan. 12, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's ...

GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call Thursday, January 7, 2021 at 4:15 pm ET PR Newswire BEVERLY HILLS, Calif. , Jan. 4, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused o...

Announcing the filing of U.S. and international patents, GT Biopharma (GTBP) says it is expanding the clinical development of its NK cell engager (TriKE™) therapeutic platform to target HER2+, HER3+, and HER2+/HER3+ heterodimer complex breast and gastrointestinal cancers.Comp...

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers PR Newswire BEVERLY HILLS, Calif. , Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Co...